2YP Stock Chart & Stats
€1.37
-€0.01(-0.54%)
At close: 4:00 PM EDT
€1.37
-€0.01(-0.54%)
Day’s Range― - ―
52-Week Range€0.86 - €2.94
Previous CloseN/A
Volume0.00
Average Volume (3M)20.00
Market Cap
€106.61M
Enterprise Value€213.72
Total Cash (Recent Filing)€103.44M
Total Debt (Recent Filing)€169.98M
Price to Earnings (P/E)―
Beta0.79
Next Earnings
Nov 10, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.68
Shares Outstanding75,256,380
10 Day Avg. Volume0
30 Day Avg. Volume20
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.68
Price to Sales (P/S)0.54
P/FCF Ratio-704.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€1.57Price Target Upside14.92% Upside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)-0.03
Revenue Forecast (FY)€216.45M
Bulls Say, Bears Say
Bulls Say
Debt Elimination And Balance Sheet StrengthDebt elimination removes substantial interest costs and improves financial flexibility. The resulting debt-free structure gives Health Catalyst more capacity to fund core product investment, manage migration needs, and withstand operating volatility.
Improved Cash GenerationPositive operating and free cash flow represent a material improvement from negative free cash flow in prior years. This supports internal funding of technology initiatives and reduces reliance on external capital, although losses make durability important to monitor.
Operating Efficiency And Technology MixLower operating expenses and a strategic shift toward technology revenue can improve scalability over time. Technology gross margins are expected in the low 60s, providing a stronger foundation for profitability as migration costs and transition investments subside.
Bears Say
Persistent Losses And Revenue DeclinePersistent losses indicate that gross profit remains insufficient to cover the company’s cost structure and other charges. Revenue contraction further limits operating leverage, creating a durable risk that cash generation may weaken if profitability does not normalize.
Migration-Related ARR Churn RiskMigration pressure threatens recurring revenue, customer retention, and future expansion within existing accounts. Management expects to retain only about $22M of the additional at-risk ARR, implying a potentially meaningful reduction in the recurring revenue base.
Lower Revenue And Margin OutlookLower guidance reflects the Vitalware divestiture, migration costs, and deliberate reinvestment, while Q3 EBITDA is expected near breakeven. These factors constrain near-term earnings conversion and prolong the path to sustainable operating profitability.
Health Catalyst News
2YP FAQ
What was Health Catalyst’s price range in the past 12 months?
Health Catalyst lowest stock price was €0.85 and its highest was €2.94 in the past 12 months.
What is Health Catalyst’s market cap?
Health Catalyst’s market cap is €106.61M.
When is Health Catalyst’s upcoming earnings report date?
Health Catalyst’s upcoming earnings report date is Nov 10, 2026 which is in 68 days.
How were Health Catalyst’s earnings last quarter?
Health Catalyst released its earnings results on Aug 06, 2026. The company reported €0.034 earnings per share for the quarter, beating the consensus estimate of €0.026 by €0.009.
Is Health Catalyst overvalued?
According to Wall Street analysts Health Catalyst’s price is currently Undervalued.
Does Health Catalyst pay dividends?
Health Catalyst does not currently pay dividends.
What is Health Catalyst’s EPS estimate?
Health Catalyst’s EPS estimate is -0.05.
How many shares outstanding does Health Catalyst have?
Health Catalyst has 75,256,380 shares outstanding.
What happened to Health Catalyst’s price movement after its last earnings report?
Health Catalyst reported an EPS of €0.034 in its last earnings report, beating expectations of €0.026. Following the earnings report the stock price went down -28.365%.
Which hedge fund is a major shareholder of Health Catalyst?
Currently, no hedge funds are holding shares in DE:2YP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Health Catalyst Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€1.57 (14.92% Upside)
€1.57 (14.92% Upside)
Blogger Sentiment
Neutral
DE:2YP Sentiment 100%
Sector Average 60%
Sector Average 60%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-49.55%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-41.80%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Health Catalyst
Health Catalyst, Inc. equips healthcare providers with crucial data and analytical technologies, alongside specialized services. Their extensive product line features a robust, enterprise-level data and analytics platform designed specifically for the healthcare sector. They additionally offer advanced artificial intelligence (AI) and data science solutions that integrate AI seamlessly into existing business intelligence tools, thereby enhancing analytical precision. The company's services also cover population health management, which identifies areas for improvement throughout the patient care journey, offering actionable recommendations and automated processes. For financial effectiveness, they provide critical insights into cost analysis, workforce efficiency, and revenue maximization. Moreover, Health Catalyst contributes to improving quality and safety by leveraging clinical and patient safety data, sophisticated analytics, and expert consulting. They also facilitate a national data ecosystem, promoting collaborative thought leadership and shared knowledge to generate groundbreaking insights that redefine healthcare delivery. Established in 2008 and based in South Jordan, Utah, the company was formerly known as HQC Holdings, Inc. before officially becoming Health Catalyst, Inc. in March 2017.
2YP Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call communicated meaningful strategic progress: a completed divestiture that eliminated debt and interest costs, cost reductions via Project Nexus, a Q2 revenue beat and adjusted EBITDA at the high end of guidance, and continued investments in technology and AI. However, the near-term picture is constrained by the loss of Vitalware's revenue/EBITDA contribution, persistent migration-related churn and at-risk ARR, margin pressure from dual operating costs during migrations, and a lowered full-year revenue/EBITDA outlook. Management frames these as deliberate, multiyear transformation actions that improve the capital structure and position the company for long-term growth while acknowledging short-term revenue and margin headwinds.View all DE:2YP earnings summaries2YP Stock 12 Month Forecast
Average Price Target
€1.57
▲(14.92% Upside)
Technical Analysis
Evolent Health
―
Phreesia
―
Privia Health Group
―
Definitive Healthcare Corp
―
Waystar Holding Corp.
―